Budget 2026: The Roadmap for ‘Heal in India’ & Science R&D

A developed nation cannot be built on borrowed technology or a fragile healthcare system. In Union Budget 2026-27, the government has acknowledged this reality, shifting the focus from “treating illness” to “fostering innovation.”

While the headline allocation for healthcare has seen a steady rise, the real story lies in the Science & Technology allocation—specifically the operationalization of the ‘Anusandhan’ National Research Fund.

Here is how the 2026 budget aims to transform India into a global pharmacy and research hub.

1. The “Anusandhan” Era Begins

(Target Keyword: Anusandhan National Research Fund)

The highlight of the Science budget is the full-scale launch of the “Anusandhan” corpus.

• The Corpus: A massive ₹1 Lakh Crore pool (interest-free loans) is now live to encourage the private sector to scale up research and innovation.
• The Goal: To move India from “adopting technology” to “generating technology” in sunrise sectors like Deep Tech, Bio-Pharma, and Defense.
• Impact: This is a game-changer for R&D-heavy companies that previously struggled with the high cost of capital.

2. “Heal in India”: Infrastructure & Education

The budget continues the mission to make India a medical tourism destination (“Heal in India”) while strengthening domestic care.

• New Nursing Colleges: Co-location of 157 new nursing colleges with existing medical colleges is being fast-tracked to fix the global shortage of nurses.
• Sickle Cell Elimination: The mission to eliminate Sickle Cell Anemia by 2047 receives a funding boost for screening 7 crore people in tribal areas.
• Cervical Cancer: Encouragement of vaccination for girls aged 9-14 remains a key preventive health priority.

3. Pharma & MedTech: Ending Import Dependence

(Target Keyword: Medical device industry budget)

India is known as the “Pharmacy of the World” for generics, but we still import high-end medical devices (like MRI machines and stents).

• MedTech Parks: The budget proposes new incentives for manufacturing high-end medical devices domestically.
• Pharma PLI: Continued support for the Production Linked Incentive (PLI) scheme to boost the manufacturing of Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), reducing reliance on Chinese imports.

4. Visualizing the R&D Shift

To understand why the government is obsessed with R&D, look at this comparison of Gross Expenditure on R&D (GERD) as a percentage of GDP. India aims to cross the 1% mark rapidly.

Image Metadata:

• Alt Text: A bar chart comparing R&D spending (GERD) of Developed Nations (2-3%) vs India’s current (<0.7%) and India’s 2030 Target (>1%).
• Caption: The Gap: India’s “Anusandhan” push aims to bridge the R&D deficit against global peers.peers.
  
  5. Investment Outlook: Who Wins?
  If you are an investor, here is how to read these announcements:

5. Investment Outlook: Who Wins?

If you are an investor, here is how to read these announcements:

Frequently Asked Questions (FAQs)

Amit Sharma

Amit Sharma is the Lead Analyst at Invest With Bull, leveraging 11 years of market experience to simplify personal finance for salaried professionals. From mastering credit card arbitrage and navigating personal loans to structuring robust retirement and FIRE (Financial Independence, Retire Early) strategies, Amit provides data-backed, actionable analysis. His mission is to cut through complex banking jargon and deliver the unbiased research you need to achieve absolute financial freedom.

investwithbull.com/